Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8 + T-cell priming and viral control

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Duhan, Vikas ^a   Khairnar, Vishal ^a   Friedrich, Sarah Kim ^a   Zhou, Fan ^a   Gassa, Asmae ^a,b   Honke, Nadine ^a   Shaabani, Namir ^a   Gailus, Nicole ^a   Botezatu, Lacramioara ^a   Khandanpour, Cyrus ^a   Dittmer, Ulf ^a   Haüssinger, Dieter ^c   Recher, Mike ^d   Hardt, Cornelia ^a   Lang, Philipp A ^c   Lang, Karl S ^a,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

ANIMAL; CD8+ T LYMPHOCYTE; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MOUSE; SPLEEN; VIROLOGY; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID TISSUE; MICE; SPLEEN; VIRUS DISEASES; VIRUS REPLICATION;

EID: 84955513083     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19191     Document Type: Article

References (36)

1. Slifka, M. K. Immunological memory to viral infection. Curr. Opin. Immunol. 16, 443-450 (2004).
2. World Health Organization. WHO recommendations for routine immunization-summary tables. (2015) Available at: www.who.int/immunization/policy/immunization-tables/en/. (Accessed 10th July 2015).
3. Robbins, J. B., Schneerson, R., Szu, S. C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171, 1387-1398 (1995).
4. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401-409 (2008).
5. Law, M., Hangartner, L. Antibodies against viruses: passive and active immunization. Curr. Opin. Immunol. 20, 486-492 (2008).
6. Twigg, H. L., 3rd. Humoral immune defense (antibodies): recent advances. Proc. Am. Thorac. Soc. 2, 417-421 (2005).
7. Burton, D. R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713 (2002).
8. Miller, J. D. et al. Differentiation of CD8 T cells in response to acute and chronic viral infections: implications for HIV vaccine development. Curr. Drug Targets Infect. Disord. 5, 121-129 (2005).
9. Garrod, T. J. et al. Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Res. 192, 25-33 (2014).
10. Zanetti, M., Castiglioni, P., Ingulli, E. Principles of memory CD8 T-cells generation in relation to protective immunity. Adv. Exp. Med. Biol. 684, 108-125 (2010).
11. Butler, N. S., Nolz, J. C., Harty, J. T. Immunologic considerations for generating memory CD8 T cells through vaccination. Cell. Microbiol. 13, 925-933 (2011).
12. Zinkernagel, R. M., Hengartner, H. On immunity against infections and vaccines: credo 2004. Scand. J. Immunol. 60, 9-13 (2004).
13. Moskophidis, D., Lechner, F., Pircher, H., Zinkernagel, R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758-761 (1993).
14. Honke, N. et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat. Immunol. 13, 51-57 (2012).
15. Honke, N. et al. Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. PLoS Pathog. 9, e1003650 (2013).
16. Recher, M. et al. Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat. Med. 13, 1316-1323 (2007).
17. Recher, M. et al. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 5, 934-942 (2004).
18. Woodland, D. L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25, 98-104 (2004).
19. Hangartner, L., Zinkernagel, R. M., Hengartner, H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6, 231-243 (2006).
20. Wiesel, M., Walton, S., Richter, K., Oxenius, A. Virus-specific CD8 T cells: activation, differentiation and memory formation. APMIS 117, 356-381 (2009).
21. Zinkernagel, R. M., Hengartner, H. Protective 'immunity' by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called 'immunological memory'. Immunol. Rev. 211, 310-319 (2006).
22. Rosen, J. B. et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin. Infect. Dis. 58, 1205-1210 (2014).
23. Chapman, T. J., Lambert, K., Topham, D. J. Rapid reactivation of extralymphoid CD4 T cells during secondary infection. PloS One 6, e20493 (2011).
24. Brown, T. A., Murphy, B. R., Radl, J., Haaijman, J. J., Mestecky, J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J. Clin. Microbiol. 22, 259-264 (1985).
25. Michaud, H. A. et al. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 6, e1000948 (2010).
26. Forthal, D. N., Moog, C. Fc receptor-mediated antiviral antibodies. Curr. Opin. HIV AIDS 4, 388-393 (2009).
27. Posch, W. et al. Complement-opsonized HIV-1 overcomes restriction in dendritic cells. PLoS Pathog. 11, e1005005 (2015).
28. Park, S. H., Rehermann, B. Immune responses to HCV and other hepatitis viruses. Immunity 40, 13-24 (2014).
29. Bostan, N., Mahmood, T. An overview about hepatitis C: a devastating virus. Crit. Rev. Microbiol. 36, 91-133 (2010).
30. Park, S. H. et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat. Med. 19, 1638-1642 (2013).
31. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005).
32. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
33. Wilkins, B. S., Davis, Z., Lucas, S. B., Delsol, G., Jones, D. B. Splenic marginal zone atrophy and progressive CD8+ T-cell lymphocytosis in HIV infection: a study of adult post-mortem spleens from Cote d'Ivoire. Histopathology 42, 173-185 (2003).
34. Withehead, A., Noy, A. Successful treatment of marginal zone lymphoma with splenectomy alone despite HIV infection. AIDS 21, 1655-1656 (2007).
35. Battegay, M. et al. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24-or 96-well plates. J. Virol. Methods 33, 191-198 (1991).
36. Flatz, L. et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16, 339-345 (2010).